AMANTA reports Rs 3.31 cr profit as inflationary costs pressure Q1FY27
Management linked Q1 EBITDA to inflationary costs and overheads; captive solar generation began at the end of the quarter.
Filed 05 Aug 2026, 18:34 IST · after market close · AMANTA (AMANTA)
Key takeaways
- AMANTA reported standalone net profit of Rs 3.31 cr in Q1FY27 after Rs 6 cr of interest and Rs 4.69 cr of depreciation.
- Management said Q1FY27 EBITDA of Rs 15 cr was affected by inflationary cost increases and overheads, with operating margin at 21.13%.
- The company said its 10.8 MW captive solar plant began generation at the end of Q1FY27 and is expected to deliver Rs 9 cr in annual power-cost savings from FY27 onwards.
Interest and depreciation narrowed the operating-to-net profit conversion
AMANTA reported standalone revenue of Rs 68.8 cr and operating profit of Rs 14.54 cr in Q1FY27. Interest of Rs 6 cr and depreciation of Rs 4.69 cr absorbed much of operating profit before tax, which stood at Rs 4.49 cr. Tax of Rs 1.18 cr brought net profit to Rs 3.31 cr.
Inflation and overheads weighed on the Q1 margin
Management said Q1FY27 EBITDA of Rs 15 cr was affected by inflationary cost increases and overheads. The commentary identifies input-cost and fixed-overhead pressure as the main constraint on the 21.13% operating margin. Other income was Rs 0.64 cr, so the quarter's operating performance remained the central contributor to reported profit.
Captive solar generation started as expansion approaches
The company said its 10.8 MW captive solar plant began generation at the end of Q1FY27 and is expected to provide Rs 9 cr in annual power-cost savings from FY27 onwards. Management said operations from the expansion are likely to commence from Q2FY27, alongside continued work on new products. The presentation also identified inhalation solutions, ophthalmics and respiratory products as new offerings.
Results were filed after market close
AMANTA filed these standalone Q1FY27 results after market close on 5 August 2026. The results are therefore covered here without a post-results market reaction.
Q1FY27 at a glance
Standalone figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹69 cr |
| Other income | ₹1 cr |
| Expenses | ₹54 cr |
| Operating profit | ₹15 cr |
| Operating margin (%) | 21.13% |
| Interest | ₹6 cr |
| Depreciation | ₹5 cr |
| Profit before tax | ₹4 cr |
| Tax | ₹1 cr |
| Net profit | ₹3 cr |
| EPS (₹) | ₹0.85 |
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
This quarter
- Captive solar generation started at the end of Q1FY27.
Guidance & outlook
- The solar plant is expected to provide INR 9 Cr in annual power-cost savings and benefits from FY27 onwards.
- Operations from the expansion are likely to commence from Q2FY27, with further focus on new product development.
Planned next quarter
- Operations from the expansion are likely to commence from Q2FY27.
New products
- New offerings include inhalation solutions, ophthalmics, and respiratory products.
New initiatives
- The company is implementing a 10.8 MW captive solar plant to structurally lower power costs.
- The company is focusing on new product development to enrich its product portfolio.
Competition
- SteriPort is described as dominant in the polypropylene IV bottle segment and was the first in India to shift from BFS to ISBM.
Problems & risks
- Q1FY27 EBITDA was affected by inflationary cost increases and overheads.
What to watch
- Whether operating margin holds above 21.13%.
- Whether expansion operations commence from Q2FY27, as management said.
- Whether the 10.8 MW solar plant begins contributing toward the stated Rs 9 cr annual power-cost savings.